Secukinumab Provides Rapid and Sustained Pain Relief in Ankylosing Spondylitis, as Well as Improvements...
Secukinumab, a fully human monoclonal antibody that selectively neutralizes IL-17A, has shown sustained efficacy in patients with active ankylosing spondylitis (AS), a form of arthritis that causes inflammation of the spinal joints (vertebrae) that can lead to severe, chronic pain and discomfort.
For patients with psoriatic arthritis (PsA), a chronic disease characterized by a form of inflammation of the skin and joints, the optimal aim of treatment is very low disease activity (VLDA) or remission. Minimal disease activity (MDA) and low disease activity (LDA) are also good results of treatment.
New research presented at the 2017 annual meeting of the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP) shows that Medicare beneficiaries with lupus who live in areas with higher proportions of African Americans, fewer hospitals and less access to health professionals have lower adherence to their lupus therapy.
Systemic sclerosis, otherwise known as scleroderma, is a rare but serious autoimmune disease that hardens and tightens the skin and connective tissue. It is associated with severe complications, including kidney disease, pulmonary arterial hypertension, lung inflammation or gastrointestinal problems.
A large percentage of patients with end-stage osteoarthritis use opioids to manage their chronic pain, particularly younger patients and those who have symptoms of depression, according to a research team presenting study results at the 2017 annual meeting of the American College of Rheumatology (ACR) and the Association of Rheumatology Health Professionals (ARHP).